CHELMSFORD, MA / ACCESSWIRE / November 14, 2024 / Harte Hanks, Inc. (NASDAQ:HHS), a leading global customer experience company focused on bringing companies closer to customers for over 100 years, tod ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback